These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35412467)

  • 1. Where Opioid Overdose Patients Live Far From Treatment: Geospatial Analysis of Underserved Populations in New York State.
    Abell-Hart K; Rashidian S; Teng D; Rosenthal RN; Wang F
    JMIR Public Health Surveill; 2022 Apr; 8(4):e32133. PubMed ID: 35412467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic.
    Dadiomov D; Bolshakova M; Mikhaeilyan M; Trotzky-Sirr R
    Harm Reduct J; 2022 Jun; 19(1):69. PubMed ID: 35768817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacy-related buprenorphine access barriers: An audit of pharmacies in counties with a high opioid overdose burden.
    Kazerouni NJ; Irwin AN; Levander XA; Geddes J; Johnston K; Gostanian CJ; Mayfield BS; Montgomery BT; Graalum DC; Hartung DM
    Drug Alcohol Depend; 2021 Jul; 224():108729. PubMed ID: 33932744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simulating the Simultaneous Impact of Medication for Opioid Use Disorder and Naloxone on Opioid Overdose Death in Eight New York Counties.
    Cerdá M; Hamilton AD; Hyder A; Rutherford C; Bobashev G; Epstein JM; Hatna E; Krawczyk N; El-Bassel N; Feaster DJ; Keyes KM
    Epidemiology; 2024 May; 35(3):418-429. PubMed ID: 38372618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statewide Availability of Buprenorphine/Naloxone in Acute Care Hospitals.
    Pham S; Haigh A; Barrett E
    J Addict Med; 2022 Jan-Feb 01; 16(1):e48-e51. PubMed ID: 33758118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-Overdose Extended-Release Buprenorphine Initiation Facilitated by a Partnership Between Emergency Medical Services and an Outpatient Substance Use Disorder Observation Unit.
    Taylor JL; Gott J; Weisenthal K; Colicchio P; Dyer S; Komaromy MS
    Subst Use Addctn J; 2024 Oct; 45(4):771-776. PubMed ID: 38736211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states.
    Hill LG; Loera LJ; Torrez SB; Puzantian T; Evoy KE; Ventricelli DJ; Eukel HN; Peckham AM; Chen C; Ganetsky VS; Yeung MS; Zagorski CM; Reveles KR
    Drug Alcohol Depend; 2022 Aug; 237():109518. PubMed ID: 35691255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study protocol for the Respond to Prevent Study: a multi-state randomized controlled trial to improve provision of naloxone, buprenorphine and nonprescription syringes in community pharmacies.
    Green TC; Bratberg J; Irwin AN; Boggis J; Gray M; Leichtling G; Bolivar D; Floyd A; Al-Jammali Z; Arnold J; Hansen R; Hartung D
    Subst Abus; 2022; 43(1):901-905. PubMed ID: 35213293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Geographic and specialty distribution of US physicians trained to treat opioid use disorder.
    Rosenblatt RA; Andrilla CH; Catlin M; Larson EH
    Ann Fam Med; 2015; 13(1):23-6. PubMed ID: 25583888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neighborhood-Level and Spatial Characteristics Associated with Lay Naloxone Reversal Events and Opioid Overdose Deaths.
    Rowe C; Santos GM; Vittinghoff E; Wheeler E; Davidson P; Coffin PO
    J Urban Health; 2016 Feb; 93(1):117-30. PubMed ID: 26800987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Naloxone and Buprenorphine Prescribing Following US Emergency Department Visits for Suspected Opioid Overdose: August 2019 to April 2021.
    Chua KP; Dahlem CHY; Nguyen TD; Brummett CM; Conti RM; Bohnert AS; Dora-Laskey AD; Kocher KE
    Ann Emerg Med; 2022 Mar; 79(3):225-236. PubMed ID: 34802772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expanding access to Medication for Opioid Use Disorder (MOUD) in jails: A comprehensive program evaluation.
    Pourtaher E; Gelberg KH; Fallico M; Ellendon N; Li S
    J Subst Use Addict Treat; 2024 Jun; 161():209248. PubMed ID: 38081540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Local health departments and the implementation of evidence-based policies to address opioid overdose mortality.
    Feuerstein-Simon R; Lowenstein M; Sharma M; Dupuis R; Luna Marti X; Cannuscio CC
    Subst Abus; 2020; 41(4):468-474. PubMed ID: 32213045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient, prescriber, and Community factors associated with filled naloxone prescriptions among patients receiving buprenorphine 2017-18.
    Stein BD; Jones CM; Smart R; Sheng F; Sorbero M
    Drug Alcohol Depend; 2021 Apr; 221():108569. PubMed ID: 33578296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accessing Take-Home Naloxone in British Columbia and the role of community pharmacies: Results from the analysis of administrative data.
    Moustaqim-Barrette A; Papamihali K; Mamdani Z; Williams S; Buxton JA
    PLoS One; 2020; 15(9):e0238618. PubMed ID: 32915834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Naloxone administration by law enforcement officers in New York State (2015-2020).
    Pourtaher E; Payne ER; Fera N; Rowe K; Leung SJ; Stancliff S; Hammer M; Vinehout J; Dailey MW
    Harm Reduct J; 2022 Sep; 19(1):102. PubMed ID: 36123614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disparities in opioid overdose survival and naloxone administration in Pennsylvania.
    Holmes LM; Rishworth A; King BH
    Drug Alcohol Depend; 2022 Sep; 238():109555. PubMed ID: 35810621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of naloxone education for patients receiving buprenorphine-containing prescriptions indicated for opioid use disorder at an independent community pharmacy.
    Hines KL; Garofoli GK; Garofoli MP; Elswick BM; Winstanley EL
    J Am Pharm Assoc (2003); 2020; 60(6):e205-e214. PubMed ID: 32800678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Building bridges to outpatient treatment services for post-overdose care via paramedic buprenorphine field initiation.
    Belden C; Kopak A; Coules C; Friesen T; Hall J; Shukla S
    J Subst Use Addict Treat; 2024 Jul; 162():209364. PubMed ID: 38626851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting community-based naloxone distribution using opioid overdose death rates: A descriptive analysis of naloxone rescue kits and opioid overdose deaths in Massachusetts and Rhode Island.
    Zang X; Macmadu A; Krieger MS; Behrends CN; Green TC; Morgan JR; Murphy SM; Nolen S; Walley AY; Schackman BR; Marshall BD
    Int J Drug Policy; 2021 Dec; 98():103435. PubMed ID: 34482264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.